TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27695989

Group type: EXPERIMENTAL
Intervention: Low-level exercise echocardiography (measured E/e' at rest and during low-level exercise)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-level exercise echocardiography
Number of subjects: 60
Study: 26306902

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib (arm B)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Chemotherapy (arm A)
Number of subjects: 46
Study: 23508747

Group type: EXPERIMENTAL
Intervention: IMC-facilitated approach (Group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional single transseptal big CB approach (Group A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 21985880

Group type: EXPERIMENTAL
Intervention: Powered toothbrushes under supervised conditions
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Powered toothbrushes under unsupervised conditions
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Manual toothbrushes under supervised conditions
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Manual toothbrushes under unsupervised conditions
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Supervised brushing (both brushes)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Unsupervised brushing (both brushes)
Number of subjects: 200
Study: 19197740

Group type: EXPERIMENTAL
Intervention: Interactive tutorial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive tutorial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preference for tutorial type
Number of subjects: 0
Study: 17463072

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFN beta-1a) therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 54
Study: 15927922

Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg daily for 3 months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EGb 761 (150 microg/ml incubation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (incubation)
Number of subjects: 12
Study: 11487602

Group type: EXPERIMENTAL
Intervention: Unsupervised exercise (after 10 weeks of supervised weight-lifting)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (lectures for 10 weeks)
Number of subjects: 32
Study: 10960463

Group type: EXPERIMENTAL
Intervention: PEG‐Intron 0.35, 0.7, or 1.4 microg/kg subcutaneously weekly for 24 weeks plus ribavirin 600, 800, or 1,000 to 1,200 mg orally daily.
Number of subjects: 72

Group type: COMPARATOR
Intervention: PEG‐Intron alone (0.35, 0.7, or 1.4 microg/kg subcutaneously weekly for 24 weeks).
Number of subjects: 72
Study: 8704698

Group type: EXPERIMENTAL
Intervention: Post-transplant
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Post-transplant (4 months later)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pre-transplant
Number of subjects: 42
Study: 1899892

Group type: EXPERIMENTAL
Intervention: Involvement of the central nervous system (CNS) in schistosomiasis mansoni
Number of subjects: 0

Group type: COMPARATOR
Intervention: CNS involvement associated with hepatosplenic and cardiopulmonary forms
Number of subjects: 0
Study: 6661380

Group type: EXPERIMENTAL
Intervention: Brotizolam (0.25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31590438

Group type: EXPERIMENTAL
Intervention: Fibre supplementation (twice-a-day for 2 years)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 180
Study: 29122463

Group type: EXPERIMENTAL
Intervention: Two doses of TDV 3 months apart (group 1)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: One dose of TDV (group 2)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: One dose of TDV and a booster dose 1 year later (group 3)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Placebo (group 4)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Vaccine-related unsolicited adverse events
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Symptomatic, virologically confirmed dengue
Number of subjects: 1800
Study: 27575577

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at GV 26, Ex‐HN 3, bilateral LI 4, and ST 36 for 10 minutes
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control session without acupuncture
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 11
Study: 24594833

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve M-16V (3×10^9 cfu/day)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 159
Study: 22492766

Group type: EXPERIMENTAL
Intervention: Written gestational age‐specific information 1 hour before verbal counseling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gestational age‐specific verbal information
Number of subjects: 60
Study: 20156983

Group type: EXPERIMENTAL
Intervention: Active TENS (0.25 ms, 100 Hz, 15 mA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 18
Study: 18612053

Group type: EXPERIMENTAL
Intervention: Intervention group patients included their chosen support person in the education session and the support persons received newsletters.
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned but implied as those who did not include a support person in the education session).
Number of subjects: 199
Study: 16098418

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 1205

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1205

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1205
Study: 11918762

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEPO)
Number of subjects: 27

Group type: COMPARATOR
Intervention: nandrolone decanoate (ND; 200 mg/week IM)
Number of subjects: 27
Study: 10633516

Group type: EXPERIMENTAL
Intervention: Fluoroshield (F releasing filled fissure sealant)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Delton (non-F nonfilled fissure sealant)
Number of subjects: 112
Study: 7495346

Group type: EXPERIMENTAL
Intervention: Patients with acute rheumatic fever and chronic rheumatic heart disease
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients with rheumatic fever
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 60
Study: 1851824

Group type: EXPERIMENTAL
Intervention: 5.0‐g sodium alginate supplement (algae‐isolate, 75% soluble fiber)
Number of subjects: 7
Study: 30239620

Group type: EXPERIMENTAL
Intervention: PrEPmate (text-messaging intervention)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 121
Study: 29908053

Group type: EXPERIMENTAL
Intervention: Quality physical activity features in Madison County parks (mean, 13)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Quality physical activity amenities in Madison County parks (mean, 25.8)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Quality incivilities in Madison County parks (mean, 1.6)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Total neighborhood parks quality physical activity resources (QPAR) index (mean, 28.7)
Number of subjects: 19
Study: 26942320

Group type: EXPERIMENTAL
Intervention: Dopamine agonist ropinirole 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine agonist ropinirole 1.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24781725

Group type: EXPERIMENTAL
Intervention: Levosimendan (12.5 mg, 0.1 µg kg(‐1) per min; n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 33
Study: 21975558

Group type: EXPERIMENTAL
Intervention: IV ibandronate 2 mg bimonthly
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: IV ibandronate 3 mg quarterly
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: IV ibandronate (previously treated with daily oral ibandronate or placebo IV)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: IV ibandronate (both regimens)
Number of subjects: 756
Study: 20499255

Group type: EXPERIMENTAL
Intervention: 1.5 mg nafamostat mesilate diluted in a 5% glucose solution
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1.5 ml 5% glucose solution (Control)
Number of subjects: 90
Study: 18065333

Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: metoprolol 100 mg/day
Number of subjects: 54
Study: 16118802

Group type: EXPERIMENTAL
Intervention: Recurrent cancer diagnosis (R group)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Disease-free status (DF group)
Number of subjects: 227
Study: 12358871

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention with feedback reports and support from a facilitator
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group with no special attention
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 185
Study: 10662480

Group type: EXPERIMENTAL
Intervention: CIP/MTZ i.v./PO (ciprofloxacin plus metronidazole, intravenous to oral)
Number of subjects: 446

Group type: COMPARATOR
Intervention: CIP/MTZ i.v. or IMI i.v. (ciprofloxacin plus metronidazole intravenous or imipenem-cilastatin intravenous)
Number of subjects: 446

Group type: COMPARATOR
Intervention: IMI i.v. (imipenem-cilastatin intravenous)
Number of subjects: 446

Group type: COMPARATOR
Intervention: CIP/MTZ i.v. (ciprofloxacin plus metronidazole intravenous)
Number of subjects: 446
Study: 7779645

Group type: EXPERIMENTAL
Intervention: Clotrimazole (500 mg pessary and 1% cream)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg bd oral dose for 1 day)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Fluconazole (150 mg single oral dose)
Number of subjects: 229
Study: 2178597

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (various doses)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Prednisolone sodium phosphate
Number of subjects: 124
Study: 6932834

Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 9
Study: 31404106

Group type: EXPERIMENTAL
Intervention: MNS autoantibody assay (combination of four autoantibodies and free/total PSA ratio)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: MNS autoantibody assays for four autoantibodies (PARK7, TARDBP, TLN1, CALD1)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PSA and free PSA
Number of subjects: 99
Study: 27933431

Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Preconditioning (RIPC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 16
Study: 25308244

Group type: EXPERIMENTAL
Intervention: Synchronous e-learning (SeL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face (FtF) teaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 24965659

Group type: EXPERIMENTAL
Intervention: Head CT Choice decision aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 22782331

Group type: EXPERIMENTAL
Intervention: IP (irinotecan/cisplatin)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: IP + ISMN (irinotecan/cisplatin with isosorbide-5-mononitrate)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: IX (irinotecan/capecitabine)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: IX + ISMN (irinotecan/capecitabine with isosorbide-5-mononitrate)
Number of subjects: 146
Study: 19008238

Group type: EXPERIMENTAL
Intervention: PMOP(enhanced)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (standard pacing)
Number of subjects: 41
Study: 16153327

Group type: EXPERIMENTAL
Intervention: Vitamin-fortified maize meal (with vitamin A, thiamine, riboflavin, and pyridoxine) for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unfortified maize meal for 12 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vitamin-fortified maize meal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unfortified maize meal
Number of subjects: 60
Study: 12854478

Group type: EXPERIMENTAL
Intervention: Continuous administration of fentanyl (1 microgram.kg‐1 before operation and 0.02 microgram.kg‐1.min‐1 during operation) and propofol (4‐10 mg.kg‐1.min‐1)
Number of subjects: 0
Study: 10372614

Group type: EXPERIMENTAL
Intervention: Duodenal feeds (D)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gastric feeds (G)
Number of subjects: 80
Study: 8911982

Group type: EXPERIMENTAL
Intervention: Exercise (bicycle ergometer for 1 hour at pulse rate 120 bpm)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Glimepiride with exercise
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Glibenclamide with exercise
Number of subjects: 167

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 167
Study: 1806034

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 250 mg as a single i.v. injection before chemotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 61
Study: 6957992

Group type: EXPERIMENTAL
Intervention: Full dose pirenzepine therapy (100 mg/day) for 28 days
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Low pirenzepine doses (50 mg/day) for 6 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Pirenzepine withdrawal (no treatment)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Antacid therapy (28 days) followed by withdrawal
Number of subjects: 44
Study: 30383298

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) + Surgical Treatment (ST)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Surgical Treatment (ST) only
Number of subjects: 16
Study: 28306591

Group type: EXPERIMENTAL
Intervention: High PEEP group (PEEP levels of 12 cmH2O and RM)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Low PEEP group (PEEP levels of 2 cmH2O or less without RM)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patients who developed PPCs
Number of subjects: 63
Study: 25480450

Group type: EXPERIMENTAL
Intervention: Culturally and linguistically responsive (CLR) instruction using a bilingual modality (Spanish and English)
Number of subjects: 42

Group type: COMPARATOR
Intervention: English culturally responsive (ECR) instruction using English only
Number of subjects: 42
Study: 22846413

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg 3 times daily and vitamin E 400 IU daily for 6 months
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard follow up
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pentoxifylline/vitamin E
Number of subjects: 53
Study: 21701421

Group type: EXPERIMENTAL
Intervention: Eritoran 45 mg/105 mg
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 18081358

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.02 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.01 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.01 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study: 16736338

Group type: EXPERIMENTAL
Intervention: TIES incision
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TI incision
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TIE incision
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TI and TIE incisions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TIE group
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 8
Study: 14665609

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a (3 megaunits three times per week for 2 years or until recurrence)
Number of subjects: 674

Group type: COMPARATOR
Intervention: No further treatment (control)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 674
Study: 11450490

Group type: EXPERIMENTAL
Intervention: Vitrectomy (standard pars plana vitrectomy with creation of a posterior vitreous detachment)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: No preoperative macular photocoagulation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Preoperative macular laser treatment
Number of subjects: 21
Study: 9395758

Group type: EXPERIMENTAL
Intervention: 6 x 10(6) U of recombinant interferon-alpha-2a (IFN alpha-2a) six days a week for the first two weeks, then 6 x 10(6) U three days a week for the next 22 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 9 x 10(6) U of recombinant interferon-alpha-2a (IFN alpha-2a) six days a week for the first two weeks, then 6 x 10(6) U three days a week for the next 22 weeks
Number of subjects: 61
Study: 8185877

Group type: EXPERIMENTAL
Intervention: Transdermal physostigmine
Number of subjects: 12
Study: 2967625

Group type: EXPERIMENTAL
Intervention: Intracoronary NTG (200 micrograms)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sublingual NIF (10 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control occlusion period
Number of subjects: 26
Study: 31954959

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral-based physical therapy (CBPT-ACLR) intervention
Number of subjects: 8
Study: 29908420

Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose followed by 90 mg twice daily maintenance dose
Number of subjects: 3799

Group type: COMPARATOR
Intervention: Clopidogrel 300 mg loading dose followed by 75 mg/day maintenance dose
Number of subjects: 3799

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 3799

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3799
Study: 27866517

Group type: EXPERIMENTAL
Intervention: Systematic, integrated and highly‐intensive pulmonary rehabilitation for 7 days including pharmacotherapy and physical rehabilitation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Systematic, integrated and highly‐intensive pulmonary rehabilitation for 7 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard preoperative care
Number of subjects: 48
Study: 24740371

Group type: EXPERIMENTAL
Intervention: Daclizumab high‐yield process
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23327958

Group type: EXPERIMENTAL
Intervention: ω‐3 fish oil lipid emulsion (0.2 g×kg(‐1)×d(‐1), 10%) for 14 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 53
Study: 20679143

Group type: COMPARATOR
Intervention: NVP 0 g
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NVP 2.5 g
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NVP 5 g
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NVP 7.5 g
Number of subjects: 20
Study: 18836346

Group type: EXPERIMENTAL
Intervention: Ropinirole 0.5 to 6.0 mg/d twice daily
Number of subjects: 359

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 359
Study: 16671257

Group type: EXPERIMENTAL
Intervention: Spinal morphine (15 microg x Kg(‐1))
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intravenous morphine (0.3 mg x Kg(‐1))
Number of subjects: 59
Study: 14714845

Group type: EXPERIMENTAL
Intervention: Ceramic abutments
Number of subjects: 32

Group type: COMPARATOR
Intervention: Titanium abutments
Number of subjects: 32
Study: 10722985

Group type: EXPERIMENTAL
Intervention: Community activities intervention
Number of subjects: 352
Study: 9196161

Group type: EXPERIMENTAL
Intervention: Gallium nitrate plus fluorouracil (5-FU)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: M-VAC as second-line therapy after gallium nitrate/5-FU
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gallium nitrate and 5-FU
Number of subjects: 34

Group type: COMPARATOR
Intervention: M-VAC
Number of subjects: 34
Study: 1542854

Group type: EXPERIMENTAL
Intervention: Interleukin-4
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Interleukin-4 with concomitant indomethacin
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Interleukin-4 with concomitant ranitidine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Interleukin-2 and indomethacin without interleukin-4
Number of subjects: 73
Study: 3539028

Group type: EXPERIMENTAL
Intervention: Inositol (120-160 mg/kg/day) administered by the ingastric or intravenous route
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 29448861

Group type: EXPERIMENTAL
Intervention: Self-retaining barbed suture (SRBS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional absorbable polyglactin suture (non-SRBS group)
Number of subjects: 60
Study: 27928815

Group type: EXPERIMENTAL
Intervention: 20 mg/daily tadalafil
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: 0.4 mg/daily tamsulosin
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Combination of 0.4 mg/daily tamsulosin and 20 mg/daily tadalafil
Number of subjects: 183
Study: 24290078

Group type: EXPERIMENTAL
Intervention: Unsupportive maternal behavior at 8 months
Number of subjects: 1752

Group type: COMPARATOR
Intervention: Overly involved maternal behavior
Number of subjects: 1752
Study: 21999423

Group type: EXPERIMENTAL
Intervention: LESS-TEP
Number of subjects: 44

Group type: COMPARATOR
Intervention: LAP-TEP
Number of subjects: 44
Study: 19011935

Group type: EXPERIMENTAL
Intervention: Prosthetic mesh in a sublay position
Number of subjects: 54
Study: 17334518

Group type: EXPERIMENTAL
Intervention: Low-dose ZK-807834
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Medium-dose ZK-807834
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-dose ZK-807834
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16281889

Group type: EXPERIMENTAL
Intervention: Concept of equipoise as used by neonatologists during interviews
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exploration of equipoise at individual and community levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Balancing of benefit and harm in the context of equipoise
Number of subjects: 30
Study: 11251005

Group type: EXPERIMENTAL
Intervention: Oral topotecan (2.3 mg/m²/day for 5 days, every 21 days)
Number of subjects: 106

Group type: COMPARATOR
Intervention: IV topotecan (1.5 mg/m²/day for 5 days, every 21 days)
Number of subjects: 106